PL2293804T3 - Wirus opryszczki pospolitej (HSV) o zmodyfikowanym tropizmie, jego zastosowanie i sposób przygotowania - Google Patents

Wirus opryszczki pospolitej (HSV) o zmodyfikowanym tropizmie, jego zastosowanie i sposób przygotowania

Info

Publication number
PL2293804T3
PL2293804T3 PL08789969T PL08789969T PL2293804T3 PL 2293804 T3 PL2293804 T3 PL 2293804T3 PL 08789969 T PL08789969 T PL 08789969T PL 08789969 T PL08789969 T PL 08789969T PL 2293804 T3 PL2293804 T3 PL 2293804T3
Authority
PL
Poland
Prior art keywords
hsv
preparation
herpes simplex
simplex virus
modified tropism
Prior art date
Application number
PL08789969T
Other languages
English (en)
Inventor
Gabriella Campadelli
Laura Menotti
Original Assignee
Univ Bologna Alma Mater Studiorum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bologna Alma Mater Studiorum filed Critical Univ Bologna Alma Mater Studiorum
Publication of PL2293804T3 publication Critical patent/PL2293804T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16633—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL08789969T 2008-05-29 2008-05-29 Wirus opryszczki pospolitej (HSV) o zmodyfikowanym tropizmie, jego zastosowanie i sposób przygotowania PL2293804T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IT2008/000358 WO2009144755A1 (en) 2008-05-29 2008-05-29 Herpes simplex virus (hsv) with modified tropism, uses and process of preparation thereof
EP08789969.6A EP2293804B1 (en) 2008-05-29 2008-05-29 Herpes simplex virus (hsv) with modified tropism, uses and process of preparation thereof

Publications (1)

Publication Number Publication Date
PL2293804T3 true PL2293804T3 (pl) 2014-03-31

Family

ID=40032777

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13168599T PL2700405T3 (pl) 2008-05-29 2008-05-29 Wirus opryszczki pospolitej (HSV) o zmodyfikowanym tropizmie, jego wykorzystanie i proces przygotowania
PL08789969T PL2293804T3 (pl) 2008-05-29 2008-05-29 Wirus opryszczki pospolitej (HSV) o zmodyfikowanym tropizmie, jego zastosowanie i sposób przygotowania

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL13168599T PL2700405T3 (pl) 2008-05-29 2008-05-29 Wirus opryszczki pospolitej (HSV) o zmodyfikowanym tropizmie, jego wykorzystanie i proces przygotowania

Country Status (11)

Country Link
US (2) US9157071B2 (pl)
EP (2) EP2700405B1 (pl)
JP (1) JP5683455B2 (pl)
AU (1) AU2008357065B2 (pl)
DK (2) DK2293804T3 (pl)
ES (2) ES2667622T3 (pl)
HU (1) HUE037311T2 (pl)
NO (1) NO2700405T3 (pl)
PL (2) PL2700405T3 (pl)
PT (2) PT2700405T (pl)
WO (1) WO2009144755A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9593347B2 (en) 2010-04-16 2017-03-14 University of Pittsburgh—of the Commonwealth System of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors
ES2810800T3 (es) 2013-10-28 2021-03-09 Univ Pittsburgh Commonwealth Sys Higher Education Vector de HSV oncolítico
DK3256570T3 (da) * 2015-02-11 2021-06-14 Univ Bologna Alma Mater Studiorum Retargeteret herpesvirus med en glycoprotein H-fusion
JP2019508063A (ja) 2016-01-27 2019-03-28 オンコラス， インコーポレイテッド 腫瘍溶解性ウイルスベクター及びその使用
KR20190020727A (ko) * 2016-06-09 2019-03-04 알마마 테르 스투디오룸 유니베르시타‘ 디 볼로냐 변형된 당단백질 b를 갖는 헤르페스 바이러스
KR20190015544A (ko) * 2016-06-09 2019-02-13 알마마 테르 스투디오룸 유니베르시타‘ 디 볼로냐 변형된 당단백질 d를 갖는 헤르페스 바이러스
EP3478321A4 (en) 2016-06-30 2020-04-22 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
GB201616365D0 (en) * 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
WO2019023483A1 (en) 2017-07-26 2019-01-31 Oncorus, Inc. ONCOLYTIC VIRAL VECTORS AND USES THEREOF
AU2018323502B2 (en) * 2017-08-30 2023-01-12 Km Biologics Co., Ltd. Modified HSV gD protein and vaccine containing same
JP2021508477A (ja) 2017-12-29 2021-03-11 オンコラス， インコーポレイテッド 治療用ポリペプチドの腫瘍溶解性ウイルス送達
WO2020006486A1 (en) * 2018-06-29 2020-01-02 Krystal Biotech, Inc. Compositions and methods for antibody delivery
EP3887529A4 (en) * 2018-11-28 2022-08-31 The Brigham & Women's Hospital, Inc. NEXT GENERATION REGULABLE FUSOGENIC ONCOLYTIC HERPES SIMPLEX VIRUS TYPE 1 VIRUS AND METHODS OF USE
CA3124523A1 (en) * 2019-01-03 2020-07-09 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
JP2023502099A (ja) * 2019-11-18 2023-01-20 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド コドン最適化された新世代の調節可能な融合性腫瘍溶解性単純ヘルペスウイルス１型ウイルスおよび使用方法
CN115843313B (zh) * 2020-06-12 2025-09-05 吉赛尔美德公司 用于多重靶向的重组单纯疱疹病毒及其用途
CN112501137B (zh) * 2020-11-11 2023-10-20 深圳先进技术研究院 一种神经环路标记系统
CN113969287B (zh) * 2021-10-22 2024-05-28 中国科学院深圳先进技术研究院 重组单纯疱疹病毒的亲和筛选细胞系及其构建方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1282721C (en) 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
AU737910B2 (en) 1997-01-31 2001-09-06 Regents Of The University Of California, The Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
US6080399A (en) 1998-04-23 2000-06-27 Arch Development Corporation Vaccine adjuvants for immunotherapy of melanoma
US6656718B2 (en) 2000-07-07 2003-12-02 Cancer Research Technology Limited Modified carboxypeptidase enzymes and their use
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP1998266A3 (en) 2001-02-19 2009-02-11 Merck Patent GmbH Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
US20030007974A1 (en) 2001-05-30 2003-01-09 Nanus David M. Endopeptidase/anti-PSMA antibody fusion proteins for treatment of cancer
GB0203285D0 (en) * 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
US20040115688A1 (en) 2002-04-19 2004-06-17 Cheung Irene Y. Detection of gd2 synthase mrna and uses thereof
AU2003282691A1 (en) 2002-10-07 2004-05-04 University Of Chicago Targeting of herpes simplex virus to specific receptors
US20070243170A1 (en) * 2002-10-07 2007-10-18 The University Of Chicago Targeting of Herpes Simplex Virus to Specific Receptors
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
AU2006304804B2 (en) 2005-10-21 2011-06-02 Vertex Pharmaceuticals Incorporated Modified proteases that inhibit complement activation
US20080003202A1 (en) 2006-03-28 2008-01-03 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
EP2423305A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
GB0714578D0 (en) * 2007-07-26 2007-09-05 Crusade Lab Ltd Viruses

Also Published As

Publication number Publication date
EP2293804A1 (en) 2011-03-16
US20110318268A1 (en) 2011-12-29
NO2700405T3 (pl) 2018-09-01
JP5683455B2 (ja) 2015-03-11
US9744199B2 (en) 2017-08-29
DK2293804T3 (da) 2013-08-26
PT2293804E (pt) 2013-08-29
EP2700405A1 (en) 2014-02-26
ES2667622T3 (es) 2018-05-11
EP2293804B1 (en) 2013-05-22
US9157071B2 (en) 2015-10-13
WO2009144755A1 (en) 2009-12-03
PT2700405T (pt) 2018-05-02
AU2008357065A1 (en) 2009-12-03
JP2011522532A (ja) 2011-08-04
DK2700405T3 (en) 2018-05-22
AU2008357065B2 (en) 2013-07-25
EP2700405B1 (en) 2018-04-04
PL2700405T3 (pl) 2018-08-31
US20160074448A1 (en) 2016-03-17
ES2425489T3 (es) 2013-10-15
HUE037311T2 (hu) 2018-08-28

Similar Documents

Publication Publication Date Title
HUE037311T2 (hu) Módosított tropizmusú herpes simplex vírus (HSV), alkalmazásai és eljárás az elõállítására
GB2446721B (en) Herpes simplex viruses and methods of viral replication
SMT201900033T1 (it) Virus herpes simplex oncolitico e suoi usi terapeutici
IL216508A (en) Vaccines against herpes simplex virus type 1 and / or 2 and their preparations and uses
ZA201007630B (en) Stable natural color process, products and use thereof
EP2585595B8 (en) Rna molecules and uses thereof
IL211948A0 (en) Highly concentrated drug particles, formulations, suspensions and uses thereof
IL208313A0 (en) Neutralizing molecules to viral antigens
WO2010080032A3 (en) Bead-assisted viral transduction
WO2011079073A3 (en) Herpes simplex virus vaccines
EP2488985A4 (en) Detecting and responding to malware using link files
IL224935A (en) By sugarcane cilia virus and its use in the study of plant genome function
WO2012139106A3 (en) Herpes simplex virus
ZA201303254B (en) Small viral rna molecules and uses thereof
EP2298344A4 (en) USE OF A PARTICLE FROM THE INACTIVATED VIRUS OF JAPANESE ENCEPHALITIS AS ADJUVANT
EP2473629B8 (fr) Identification du tropisme cellulaire de virus
AU2010904623A0 (en) Small viral RNA molecules and uses thereof
AU2006292131A8 (en) Systems for detection and production of respiratory, herpes and enteric viruses
GB0809073D0 (en) Infection of cells by herpes simplex virus
HK1153210A (en) Neutralizing molecules to viral antigens
GB0708941D0 (en) Infection of cells by herpes simplex virus
HK1179885A (en) Inactivated varicella zoster virus vaccines, methods of production, and uses thereof
GB0609381D0 (en) Treatment using herpes simplex virus
AU2007903674A0 (en) Epitopes of Herpes Simplex virus
GB0609384D0 (en) Infection of cells by herpes simplex virus